---
title: "MDWD: Validated enzymatic therapies drive strong growth, targeting $1B+ peak sales in chronic wounds"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295787113.md"
description: "A validated enzymatic platform supports a multibillion-dollar opportunity in non-surgical tissue repair, with NexoBrid generating $17M in 2025 and EscharEx targeting a $4B U.S. market. Robust clinical data, strong financials, and strategic milestones position the company for significant growth.Original document: MediWound Ltd. [MDWD] Slides Release — Aug. 13 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-13T11:06:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295787113.md)
  - [en](https://longbridge.com/en/news/295787113.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295787113.md)
generator: "portal-rs"
---

# MDWD: Validated enzymatic therapies drive strong growth, targeting $1B+ peak sales in chronic wounds

A validated enzymatic platform supports a multibillion-dollar opportunity in non-surgical tissue repair, with NexoBrid generating $17M in 2025 and EscharEx targeting a $4B U.S. market. Robust clinical data, strong financials, and strategic milestones position the company for significant growth.

Original document: MediWound Ltd. \[MDWD\] Slides Release — Aug. 13 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [MDWD.US](https://longbridge.com/en/quote/MDWD.US.md)

## Related News & Research

- [MediWound posts investor presentation on enzymatic burn and chronic-wound therapies NexoBrid, EscharEx](https://longbridge.com/en/news/295787062.md)
- [MediWound (NASDAQ:MDWD) Issues Earnings Results](https://longbridge.com/en/news/295866831.md)
- [Anthropic's IPO: Is Wall Street Ready for a $2 Trillion AI Bet?](https://longbridge.com/en/news/296229187.md)
- [Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene Therapy](https://longbridge.com/en/news/296478943.md)
- [Biomarin To Acquire Alesta Therapeutics To Gain Ale1, A Potential First Oral Therapy For Hypophosphatasia](https://longbridge.com/en/news/296228796.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**